RxDoctor Payments DataLook up a doctor →

David Brandli, MD

Urology · Summerville, SCNPI 1356330260

Payments from drug & device makers

$18,004in general payments, 2019–2025

Across 362 payments — averaging $49.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$7K
  • Pfizer$2K
  • Astellas Pharma US Inc$1K
  • Procept Biorobotics Corporation$1K
  • Boston Scientific$1K
  • Kowa Pharmaceuticals America, Inc.$402
  • plus $5K from 44 others

What the payments were for

  • Consulting fees$7,54842%
  • Travel & lodging$1,6329%
  • Food & beverage$8,54647%
  • Education$2782%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,004 in reported general payments places this provider in the 85th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$834,965
Medicare patients
950
Services billed
26,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide48$571,330
XtandiEnzalutamide38$508,949
OrgovyxRelugolix64$168,500
MyrbetriqMirabegron140$112,866
Abiraterone Acetate11$57,199
TrelstarTriptorelin Pamoate12$40,563
ProliaDenosumab22$38,033
XgevaDenosumab12$36,781
GemtesaVibegron44$36,382
Mirabegron ErMirabegron29$18,574
TestopelTestosterone11$13,470
Tamsulosin Hcl625$9,555
Silodosin67$7,523
Finasteride338$7,107
Testosterone Cypionate112$6,205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,322$621,815178 claims
Johnson & JohnsonErleada$6,825$571,33048 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$334$204,882108 claims
AmgenProlia, Xgeva$15$74,81534 claims
Verity Pharmaceuticals Inc.Trelstar$173$40,56312 claims
Endo Pharmaceuticals Inc.Testopel$371$13,47011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 196 urology providers in South Carolina.

Other urology in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →